Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REGROTON vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Reserpine is extensively metabolized in the liver via hydrolysis and conjugation; chlorthalidone is metabolized minimally, mainly excreted unchanged in urine, with some hepatic conjugation.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Reserpine: 96% bound to albumin and alpha-1-acid glycoprotein; Chlorthalidone: 75% bound to erythrocytes (carbonic anhydrase) and 75% to plasma proteins (albumin)
~20% bound to albumin; minimal binding to other plasma proteins.
Reserpine: 2.5-3.5 L/kg; Chlorthalidone: 3-4 L/kg; clinical meaning: extensive tissue distribution with prolonged effect due to reserpine's irreversible binding to adrenergic neurons
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: reserpine 30-50%; chlorthalidone 64%
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR 30-60 m L/min: use with caution; GFR <30 m L/min: contraindicated.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh Class A/B: reduce metoprolol dose by 50%; Class C: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended for use in pediatric patients.
Not recommended; inadequate safety data.
Initiate at half the standard dose (25 mg chlorthalidone/25 mg metoprolol) and titrate slowly due to increased risk of hypotension and electrolyte imbalance.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
May cause depression, particularly in patients with history of depression; discontinue if signs appear.,Electrolyte imbalance (hypokalemia, hyponatremia) due to chlorthalidone.,Bradycardia and orthostatic hypotension.,Use cautiously in patients with renal impairment, gout, or diabetes.,Possible increased risk of breast cancer with long-term reserpine use.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hypersensitivity to reserpine, chlorthalidone, or sulfonamides (chlorthalidone is a sulfonamide).,Active peptic ulcer disease.,History of mental depression (especially with suicidal tendencies).,Anuria or severe renal impairment.,Electrolyte depletion (untreated hypokalemia, hypercalcemia).
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-potassium foods and salt substitutes (e.g., bananas, oranges, spinach, potassium-containing salt substitutes) due to risk of hyperkalemia with chlorthalidone. Limit alcohol intake. Maintain adequate hydration but avoid excessive fluid intake. Grapefruit juice may increase atenolol absorption; limit intake. Take with food to reduce GI upset.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiac anomalies, and oral clefts due to chlorthalidone; potential for fetal hypotension and oligohydramnios. Second and third trimesters: fetal hypotension, oligohydramnios, intrauterine growth restriction, and neonatal complications including electrolyte imbalances, thrombocytopenia, and jaundice. Avoid use in pregnancy, especially during second and third trimesters.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Chlorthalidone and reserpine are excreted into breast milk. Chlorthalidone M/P ratio not established; reserpine M/P ratio approximately 0.5. Use with caution due to potential for adverse effects in the nursing infant, including electrolyte disturbances and cardiac effects. Generally not recommended during breastfeeding.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
No specific dose adjustments established. Due to increased plasma volume and renal clearance, efficacy may be reduced; however, risks generally outweigh benefits. Consider alternative antihypertensives. If used, start at lowest effective dose and monitor closely for electrolyte imbalances and hypotension.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
REGROTON is a fixed-dose combination of chlorthalidone (a thiazide-like diuretic) and atenolol (a cardioselective beta-blocker). Monitor for hypokalemia, hyperuricemia, and glucose intolerance from chlorthalidone. Atenolol may mask tachycardia in hypoglycemia and cause bradycardia; avoid abrupt discontinuation. Dosing adjustment needed in renal impairment (Cr Cl <30 m L/min contraindicated). Caution in COPD/asthma bronchospasm, peripheral vascular disease, and heart failure.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed, usually once daily, preferably in the morning to avoid nocturia.,Do not stop taking abruptly; sudden discontinuation may cause chest pain or palpitations.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or excessive thirst.,Check blood pressure and pulse regularly; keep a log.,Avoid alcohol, which can increase blood pressure lowering effects and cause dizziness.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Inform your doctor if you develop shortness of breath, wheezing, swelling, or unusual weight gain.,This drug may increase blood sugar; monitor glucose if diabetic.,Use sunscreen and protective clothing; medication can increase sun sensitivity.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REGROTON vs ALDORIL D50, answered by our medical review team.
REGROTON is a Antihypertensive Combination that works by Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REGROTON and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REGROTON is: 1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REGROTON and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REGROTON is classified as Category C. Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiac anomalies, and oral clefts due to chlorthalidone; potential for fetal hypotension and oligohyd. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.